Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Dr Preeti Joshi

Cow’s Milk Allergy in Infants and Children

A/Prof Michael Woodward AM

RSV Vaccine on the NIP – What You Need to Know

A/Prof Li-Chuen Wong

Eczema Practical Updates for General Practice

A/Prof Adrian Mar

Vitiligo – Early Detection and Early Treatment

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

12 May 2026

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD